
Life Sciences
From "Go" to "Go Public" and Beyond
We breathed life into the life sciences industry. The 1970s saw not only the emergence of the biotech sector, but also the emergence of Mintz as a leading law firm to the life sciences industry. We grew our capabilities in unison with the expansion of legal and business challenges facing industry companies.
Today, almost 50 years later, we have more than 150 practitioners providing a full spectrum of industry-specific business and litigation representation.
View our report on M&A activity in the life sciences, produced in conjunction with MergerMarket.
Share AwardsOur Experience

including public offerings, joint ventures, licensing and complex collaborations, mergers and acquisitions, divestitures, distribution deals, and private financings

Areas of Focus
Our Approach
Our roster of industry clients includes start-ups seeking their first funding and large public companies with products on the market. Venture capital firms and investment banks. And research and academic institutions. The services we provide to these clients are as varied as their challenges. Our integrated IP, regulatory, litigation, and corporate practice addresses all of their legal needs.
Mintz's reputation for excellence in the life sciences has made us the law firm of choice for investment banks including Citi, Cowen, Stifel, HC Wainwright, and Canaccord.
- IPOs, follow-on offerings, and PIPE transactions
- Reverse mergers, Form 10s, and APOs
- Securities regulatory compliance and corporate governance advice
- M&As
- Strategic collaborations and licensing
- Angel and venture capital financing
- Equity compensation
- Patent prosecution and strategy
- Patent infringement litigation
- Hatch-Waxman Paragraph IV litigation
- Alternative dispute resolution
- Trademark strategy and registration
- Trade Secrets
- FDA regulatory counseling
- Clinical trials
- Compliance planning
- Health care fraud and abuse
- Reimbursement
- Partnership and JV Disputes
- Arbitration and Mediation
- Securities
- Products Liability
- Patent Infringement
- Trade Secrets
- Contracts
What Our Clients Are Saying
Our Insights
Viewpoints

FDA’s Digital Health High Notes from 2022
February 13, 2023 |Blog

A Between The Biotech Waves Conversation With William Hicks
June 10, 2022 |Podcast
News & Press
Related Practices
- Patent Litigation
- Licensing & Technology Transactions
- Securities & Capital Markets
- Debt Financing
- Venture Capital & Emerging Companies
- Mergers & Acquisitions
- Patent Prosecution & Strategic Counseling
- FDA Regulatory
- Health Care Compliance, Fraud & Abuse, and Regulatory Counseling
- Clinical Trials & Research
- Data & Privacy Litigation and Investigations
- Medicare, Medicaid & Commercial Coverage & Reimbursement
- Product Liability & Complex Tort